Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hormone therapy in menopause. A current update].

V Seifert-Klauss1, P-M Schumm-Draeger

  • 1Frauenklinik und Poliklinik der Technischen Universität München, Klinikum rechts der Isar. vanadin.seifert-klauss@lrz.tum.de

Der Internist
|December 23, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lack of evidence that progesterone in ovulatory cycles causes breast cancer.

Climacteric : the journal of the International Menopause Society·2023
Same author

Integrated morphologic and molecular analysis of Trichomonas vaginalis, Mycoplasma hominis, and human papillomavirus using cytologic smear preparations.

Parasitology research·2018
Same author

Hormonal Smartphone Diagnostics.

Methods in molecular biology (Clifton, N.J.)·2018
Same author

[The future of healthcare : Patient-oriented, integrated, and economical at the same time].

Der Internist·2017
Same author

C-Peptide, Baseline and Postprandial Insulin Resistance after a Carbohydrate-Rich Test Meal - Evidence for an Increased Insulin Clearance in PCOS Patients?

Geburtshilfe und Frauenheilkunde·2017
Same author

Premenopausal Trabecular Bone Loss is Associated with a Family History of Fragility Fracture.

Geburtshilfe und Frauenheilkunde·2016
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
Same journal

Der Internist·2024
See all related articles

Hormone replacement therapy (HRT) shows no cardiovascular benefit and may increase risks for some women. Further studies are needed to clarify risks and benefits for specific conditions and populations.

Area of Science:

  • Endocrinology
  • Cardiovascular Medicine
  • Oncology

Context:

  • Hormone replacement therapy (HRT) was widely used for menopausal symptoms and disease prevention in the 1990s.
  • Recent large studies (HERS, WHI) question HRT's prophylactic benefits for cardiovascular disease and osteoporosis.
  • The WHI study indicated potential increased risks for cardiovascular events and breast cancer with combined estrogen-progestin therapy.

Purpose:

  • To evaluate the updated risk-benefit profile of hormone replacement therapy (HRT) in postmenopausal women.
  • To highlight the need for individualized risk assessment due to evolving HRT data.
  • To identify knowledge gaps regarding HRT in specific populations and formulations.

Summary:

  • Recent studies, including the Women's Health Initiative (WHI), suggest HRT does not reduce cardiovascular risk and may increase risks for certain conditions.

Related Experiment Videos

  • Estrogen plus progestin therapy showed increased risks for cardiovascular events and breast cancer.
  • A comprehensive risk-benefit assessment for estrogen monotherapy awaits further WHI study evaluations.

    • Impact:

    • The findings necessitate a re-evaluation of HRT guidelines and clinical practice.
    • Individualized risk assessment and clear therapeutic goals are crucial for HRT prescription.
    • Further large-scale studies are required to address HRT's efficacy and safety in perimenopausal women, osteoporosis management, and with lower-dose preparations.